cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.5281/zenodo.5839688
title: Data for the paper: "Nonlinear responses of droughts over China to volcanic eruptions at different drought phases"

description: These files are data used in the paper "Nonlinear responses of droughts over China to volcanic eruptions at different drought phases", which is published on the Geophysical Research Letters (GRL). The uploaded data are simulations from volcanic sensitivity experiments, with volcanic eruptions added in the "late-" and "early-" phases of each of the 15 drought events, respectively. The sensitivity experiments are performed using the Community Earth System Model (CESM) version 1.0.3. The compressed file "data.zip" is comprised of 4 sub-files containing variables of precipitation (prect), 500hPa vertical speed (Omega), East Asia Summer Monsoon index (EASM index), and soil moisture, respectively. In each sub-file, there are 6 txt datasets. Among the 6 ".txt" files, three of them are precipitation(EASM/Omega/Soil Moisture) anomalies centered with volcanic eruptions taking place in the late-phase of the 15 drought events (late-) in the CTRLs (with suffix "ctrl.txt"), volcanic sensitivity experiments with respect to the climatology (with suffix "vol.txt"), and volcanic sensitivity experiments with respect to the CTRLs (with suffix "vol-ctrl.txt"). Another three ".txt" files are simulations with volcanic eruptions taking place in the early-phase of the 15 drought events (early-). Each ".txt" file contains 15 time series, and each time series is 21 years' long, with 10 years before and 10 years after the volcanic eruption.
DOI: 10.5281/zenodo.5839687
title: Data for the paper: "Nonlinear responses of droughts over China to volcanic eruptions at different drought phases"

description: These files are data used in the paper "Nonlinear responses of droughts over China to volcanic eruptions at different drought phases", which is published on the Geophysical Research Letters (GRL). The uploaded data are simulations from volcanic sensitivity experiments, with volcanic eruptions added in the "late-" and "early-" phases of each of the 15 drought events, respectively. The sensitivity experiments are performed using the Community Earth System Model (CESM) version 1.0.3. The compressed file "data.zip" is comprised of 4 sub-files containing variables of precipitation (prect), 500hPa vertical speed (Omega), East Asia Summer Monsoon index (EASM index), and soil moisture, respectively. In each sub-file, there are 6 txt datasets. Among the 6 ".txt" files, three of them are precipitation(EASM/Omega/Soil Moisture) anomalies centered with volcanic eruptions taking place in the late-phase of the 15 drought events (late-) in the CTRLs (with suffix "ctrl.txt"), volcanic sensitivity experiments with respect to the climatology (with suffix "vol.txt"), and volcanic sensitivity experiments with respect to the CTRLs (with suffix "vol-ctrl.txt"). Another three ".txt" files are simulations with volcanic eruptions taking place in the early-phase of the 15 drought events (early-). Each ".txt" file contains 15 time series, and each time series is 21 years' long, with 10 years before and 10 years after the volcanic eruption.
DOI: 10.5281/zenodo.5839709
title: 3D Point Cloud Data for LiDAR-based Mobile Robot

description: LiDAR point cloud data serves as an machine vision alternative other than image. Its advantages when compared to image and video includes depth estimation and distance measurement. Low-density LiDAR point cloud data can be used to achieve navigation, obstacle detection and obstacle avoidance for mobile robots. autonomous vehicle and drones. In this metadata, we scanned over 1400 objects and classified it into 6 groups of object namely, human, cars, motorcyclist, signboard, road divider and others.
DOI: 10.5281/zenodo.5839708
title: 3D Point Cloud Data for LiDAR-based Mobile Robot

description: LiDAR point cloud data serves as an machine vision alternative other than image. Its advantages when compared to image and video includes depth estimation and distance measurement. Low-density LiDAR point cloud data can be used to achieve navigation, obstacle detection and obstacle avoidance for mobile robots. autonomous vehicle and drones. In this metadata, we scanned over 1400 objects and classified it into 6 groups of object namely, human, cars, motorcyclist, signboard, road divider and others.
DOI: 10.6084/m9.figshare.17012735
title: Supplementary Material for: Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients

description: Introduction: In peritoneal dialysis (PD) patients, the peritoneal membrane is affected by glucose-based solutions used as peritoneal dialysate fluids. This exposure leads to changes of the membrane which may eventually culminate in fibrosis and method failure. In vitro or animal studies demonstrated that glucose transporters are upregulated upon exposure to these solutions. Expression studies of glucose transporters in human peritoneum have not been reported yet. Methods: Expression of SGLT-2, GLUT1, and GLUT3 in human peritoneal biopsies was analysed by real-time polymerase chain reaction (qPCR) and Western blot analysis. The localization of these glucose transporters in the peritoneum was evaluated by immunohistochemistry using a Histo-Score. Results: Peritoneal biopsies of patients (healthy controls, uremic, PD and encapsulating peritoneal sclerosis (EPS)) were analyzed. We found evidence of SGLT-2, GLUT1 and GLUT3 expression in the peritoneal membrane. Protein expression of SGLT-2 increases with PD-duration and is significantly enhanced in EPS patients. All transporters were predominantly, but not exclusively, located adjacent to the vessel walls of the peritoneal membrane. Conclusion: Our study showed that SGLT-2, GLUT1 and GLUT3 were regularly expressed in the human peritoneum. SGLT-2 was particularly upregulated in PD patients with EPS, suggesting that this upregulation may be associated with pathological changes in the peritoneal membrane in this syndrome. Since preclinical studies in mice show that SGLT-2 inhibitors or downregulation of SGLT-2 ameliorated pathological changes in the peritoneum, SGLT-2 inhibitors may be potentially promising agents for therapy in PD patients that could reduce glucose absorption and delay functional deterioration of the peritoneal membrane in the long-term.
DOI: 10.6084/m9.figshare.17012735.v1
title: Supplementary Material for: Peritoneal expression of SGLT-2, GLUT1 and GLUT3 in peritoneal dialysis patients

description: Introduction: In peritoneal dialysis (PD) patients, the peritoneal membrane is affected by glucose-based solutions used as peritoneal dialysate fluids. This exposure leads to changes of the membrane which may eventually culminate in fibrosis and method failure. In vitro or animal studies demonstrated that glucose transporters are upregulated upon exposure to these solutions. Expression studies of glucose transporters in human peritoneum have not been reported yet. Methods: Expression of SGLT-2, GLUT1, and GLUT3 in human peritoneal biopsies was analysed by real-time polymerase chain reaction (qPCR) and Western blot analysis. The localization of these glucose transporters in the peritoneum was evaluated by immunohistochemistry using a Histo-Score. Results: Peritoneal biopsies of patients (healthy controls, uremic, PD and encapsulating peritoneal sclerosis (EPS)) were analyzed. We found evidence of SGLT-2, GLUT1 and GLUT3 expression in the peritoneal membrane. Protein expression of SGLT-2 increases with PD-duration and is significantly enhanced in EPS patients. All transporters were predominantly, but not exclusively, located adjacent to the vessel walls of the peritoneal membrane. Conclusion: Our study showed that SGLT-2, GLUT1 and GLUT3 were regularly expressed in the human peritoneum. SGLT-2 was particularly upregulated in PD patients with EPS, suggesting that this upregulation may be associated with pathological changes in the peritoneal membrane in this syndrome. Since preclinical studies in mice show that SGLT-2 inhibitors or downregulation of SGLT-2 ameliorated pathological changes in the peritoneum, SGLT-2 inhibitors may be potentially promising agents for therapy in PD patients that could reduce glucose absorption and delay functional deterioration of the peritoneal membrane in the long-term.
DOI: 10.25505/fiz.icsd.cc224sfg
title: CSD 1911225: Experimental Crystal Structure Determination

description: Related Article: Bastien Leclercq, Houria Kabbour, Françoise Damay, Claire V. Colin, Alain Pautrat, Angel M. Arevalo-Lopez, Olivier Mentré|2019|Inorg.Chem.|58|12609|doi:10.1021/acs.inorgchem.9b01303
DOI: 10.25505/fiz.icsd.cc224wrw
title: CSD 1911328: Experimental Crystal Structure Determination

description: Related Article: Sheng Li, Xiaoyuan Liu, Maurice Sorolla, II, Gregory T. McCandless, Hanlin Wu, Huifei Zhai, Julia Y. Chan, Bing Lv|2019|Inorg.Chem.|58|12017|doi:10.1021/acs.inorgchem.9b01170
DOI: 10.5517/ccdc.csd.cc2259sc
title: CCDC 1911732: Experimental Crystal Structure Determination

description: Related Article: Katie L. M. Harriman, Jesse Murillo, Elizaveta A. Suturina, Skye Fortier, Muralee Murugesu|2020|Inorg.Chem.Front.|7|4805|doi:10.1039/D0QI01007C
description: Related Article: Jesse Murillo, Katie L. M. Harriman, Elizaveta A. Suturina, Muralee Murugesu, Skye Fortier|2019|CSD Communication|||
DOI: 10.25505/fiz.icsd.cc225jng
title: CSD 1911945: Experimental Crystal Structure Determination

description: Related Article: Meixia Wu, Corey E. Frank, Yifeng Han, Mark Croft, David Walker, Martha Greenblatt, Man-Rong Li|2019|Inorg.Chem.|58|10280|doi:10.1021/acs.inorgchem.9b01425
DOI: 10.25505/fiz.icsd.cc21yq4w
title: CSD 1905388: Experimental Crystal Structure Determination

description: Related Article: Maxim Bykov, Kirill Yusenko, Elena Bykova, Anna Pakhomova, Werner Kraus, Natalia Dubrovinskaia, Leonid Dubrovinsky|2019|Eur.J.Inorg.Chem.|2019|3667|doi:10.1002/ejic.201900488
DOI: 10.25505/fiz.icsd.cc225k3y
title: CSD 1911959: Experimental Crystal Structure Determination

description: Related Article: Sergey N. Britvin, Igor V. Pekov, Maria G. Krzhizhanovskaya, Atali A. Agakhanov, Bernd Ternes, Willi Schüller, Nikita V. Chukanov|2019|Phys.Chem. Minerals|46|727|doi:10.1007/s00269-019-01034-0
DOI: 10.25505/fiz.icsd.cc225rdf
title: CSD 1912154: Experimental Crystal Structure Determination

description: Related Article: Gregor J. Hoerder, Simon Peschke, Klaus Wurst, Markus Seibald, Dominik Baumann, Ion Stoll, Hubert Huppertz|2019|Inorg.Chem.|58|12146|doi:10.1021/acs.inorgchem.9b01479
DOI: 10.25505/fiz.icsd.cc2260gs
title: CSD 1912404: Experimental Crystal Structure Determination

description: Related Article: Haijie Chen,  Jiangang He,  Christos D. Malliakas,  Constantinos C. Stoumpos,  Alexander J. E. Rettie,  Jin-Ke Bao,  Duck Young Chung,  Wai-Kwong Kwok,  Christopher Wolverton,  Mercouri G. Kanatzidis|2019|J.Am.Chem.Soc.|141|7544|doi:10.1021/jacs.9b02599
DOI: 10.25505/fiz.icsd.cc2260ht
title: CSD 1912405: Experimental Crystal Structure Determination

description: Related Article: Haijie Chen,  Jiangang He,  Christos D. Malliakas,  Constantinos C. Stoumpos,  Alexander J. E. Rettie,  Jin-Ke Bao,  Duck Young Chung,  Wai-Kwong Kwok,  Christopher Wolverton,  Mercouri G. Kanatzidis|2019|J.Am.Chem.Soc.|141|7544|doi:10.1021/jacs.9b02599
DOI: 10.25505/fiz.icsd.cc20wspd
title: CSD 1873754: Experimental Crystal Structure Determination

description: Related Article: Debora R. Barcellos, Francisco G. Coury, Antoine Emery, Michael Sanders, Jianhua Tong, Anthony McDaniel, Christopher Wolverton, Michael Kaufman, Ryan O’Hayre|2019|Inorg.Chem.|58|7705|doi:10.1021/acs.inorgchem.8b03487
DOI: 10.25505/fiz.icsd.cc20wsqf
title: CSD 1873755: Experimental Crystal Structure Determination

description: Related Article: Debora R. Barcellos, Francisco G. Coury, Antoine Emery, Michael Sanders, Jianhua Tong, Anthony McDaniel, Christopher Wolverton, Michael Kaufman, Ryan O’Hayre|2019|Inorg.Chem.|58|7705|doi:10.1021/acs.inorgchem.8b03487
DOI: 10.25505/fiz.icsd.cc20wsrg
title: CSD 1873756: Experimental Crystal Structure Determination

description: Related Article: Debora R. Barcellos, Francisco G. Coury, Antoine Emery, Michael Sanders, Jianhua Tong, Anthony McDaniel, Christopher Wolverton, Michael Kaufman, Ryan O’Hayre|2019|Inorg.Chem.|58|7705|doi:10.1021/acs.inorgchem.8b03487
DOI: 10.25505/fiz.icsd.cc226bvh
title: CSD 1912726: Experimental Crystal Structure Determination

description: Related Article: Chuan Chen, Chia-Fang Hsieh, Hsiu-Mei Lin, Ying-Feng Hsu, Jye-Shane Yang, Chih-Min Wang|2019|Dalton Trans.|48|14294|doi:10.1039/C9DT02288K
DOI: 10.25505/fiz.icsd.cc226gmd
title: CSD 1912843: Experimental Crystal Structure Determination

description: Related Article: Abudukadi Tudi, Shujuan Han, Ailijiang Abudurusuli, Haohai Yu, Zhihua Yang, Shilie Pan|2019|Dalton Trans.|48|12713|doi:10.1039/C9DT01833F
DOI: 10.25505/fiz.icsd.cc226gnf
title: CSD 1912844: Experimental Crystal Structure Determination

description: Related Article: Abudukadi Tudi, Shujuan Han, Ailijiang Abudurusuli, Haohai Yu, Zhihua Yang, Shilie Pan|2019|Dalton Trans.|48|12713|doi:10.1039/C9DT01833F
DOI: 10.25505/fiz.icsd.cc226gpg
title: CSD 1912845: Experimental Crystal Structure Determination

description: Related Article: Abudukadi Tudi, Shujuan Han, Ailijiang Abudurusuli, Haohai Yu, Zhihua Yang, Shilie Pan|2019|Dalton Trans.|48|12713|doi:10.1039/C9DT01833F
DOI: 10.25505/fiz.icsd.cc226gqh
title: CSD 1912846: Experimental Crystal Structure Determination

description: Related Article: Abudukadi Tudi, Shujuan Han, Ailijiang Abudurusuli, Haohai Yu, Zhihua Yang, Shilie Pan|2019|Dalton Trans.|48|12713|doi:10.1039/C9DT01833F
DOI: 10.25505/fiz.icsd.cc226fb2
title: CSD 1912803: Experimental Crystal Structure Determination

description: Related Article: Sebastian Bette, Tomohiro Takayama, Viola Duppel, Agnieszka Poulain, Hidenori Takagi, Robert E. Dinnebier|2019|Dalton Trans.|48|9250|doi:10.1039/C9DT01789E
DOI: 10.25505/fiz.icsd.cc226fc3
title: CSD 1912804: Experimental Crystal Structure Determination

description: Related Article: Sebastian Bette, Tomohiro Takayama, Viola Duppel, Agnieszka Poulain, Hidenori Takagi, Robert E. Dinnebier|2019|Dalton Trans.|48|9250|doi:10.1039/C9DT01789E
DOI: 10.25505/fiz.icsd.cc226cwk
title: CSD 1912758: Experimental Crystal Structure Determination

description: Related Article: Gang Yang, Long-Hua Li, Chao Wu, Mark G. Humphrey, Chi Zhang|2019|Inorg.Chem.|58|12582|doi:10.1021/acs.inorgchem.9b01262
DOI: 10.25934/pr00005657.1
title: Available IPD datapackage for study 'A 2x2 Factorial Randomized Phase III Study of Intermittent Oral Capecitabine in Combination With Intravenous Oxaliplatin (Q3W) ("XELOX") With/Without Intravenous Bevacizumab (Q3W) Versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin With Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") With/Without Intravenous Bevacizumab (Q2W) as First-line Treatment for Patients With Metastatic Colorectal Cancer'

description: This 4 arm study assessed the efficacy and safety of oral capecitabine (Xeloda) or intravenous (iv) fluorouracil/leucovorin, in combination with iv oxaliplatin (Eloxatin) with or without iv bevacizumab (Avastin), as a first-line treatment in patients with metastatic colorectal cancer. Patients were randomized to receive 1) XELOX (Xeloda 1000 mg/m^2 orally [po] twice a day [bid] on Days 1-15 + oxaliplatin in 3 week cycles), 2) FOLFOX-4 (oxaliplatin + leucovorin + fluorouracil [5-FU] in 2 week cycles), 3) XELOX + bevacizumab (7.5 mg iv on Day 1 in 3 week cycles), or 4) FOLFOX-4 + bevacizumab (5 mg iv on Day 1 in 2 week cycles).
DOI: 10.25934/pr00006066
title: EVALUATING THE ASSOCIATION BETWEEN PROTEINURIA AND THROMBOSIS AND ITS PREDICTORS IN PATIENTS TREATED WITH BEVACIZUMAB

description: Proteinurea is known to be associated with an increased risk of blood clots/thrombosis due to loss of proteins in the urine that protect against excessive clotting. Bevacizumab is a targeted agent used in many cancers including colon cancer, lung cancer, kidney cancer and others. Since some of these are rather common cancers, its use on the global level runs into several million patients annually. Bevacizumab is known to cause proteinuria (the presence of abnormal quantities of protein in the urine, which may indicate damage to the kidneys) as a side effect and is also known to increase the risk of blood clots/thrombosis. Until now, no previous study has looked at whether the presence of proteinurea could reliably predict which patients getting bevacizumab may develop blood clots/thrombosis. This study will investigate if there is association between moderate to severe proteinuria and blood clots/thrombotic events in patients who are receiving bevacizumab. We will look at patients who have received bevacizumab on various clinical trials in the past and collect information about proteinurea and development of blood clots/thrombosis in the patients. Additional information including the type of cancer being treated, prior history of blood clots/thrombosis and other cardiovascular risk factors will also be collected. Using appropriate statistical methods detailed under the "Statistical Analysis Plan" section, we will then determine whether there is a strong association between proteinurea and thrombosis in patients receiving bevacizumab. If the thrombotic risk associated with bevacizumab can be identified clinically, it would be a beneficial tool for knowing when to implement prophylaxis to prevent thrombosis in high risk patients. It would thus help to reduce worse outcomes that are associated with blood clots/thrombosis, including venous thromboembolism (VTE) recurrence, major bleeding, and increased mortality rate.
DOI: 10.25934/pr00005680.1
title: Available IPD datapackage for study 'A Phase III, Multicenter, Placebo-Controlled, Double-Blind, Randomized Clinical Trial to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva (Erlotinib) Compared With Tarceva Alone for Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) After Failure of Standard First-Line Chemotherapy'

description: This is a Phase III, multicenter, placebo-controlled, double-blind, randomized study. Approximately 650 patients will be randomized in a 1:1 ratio to one of two treatment arms.
DOI: 10.5281/zenodo.5839743
title: Terminal density reversal and the role of Ca2+ in red blood cells clearance of healthy individuals

description: Density reversal of senescent red blood cells (RBCs) has been known for more than ten years, yet the identity of the candidate protein(s) is still elusive. While performing Percoll density gradient separation of RBCs from healthy individuals and their subsequent characterization, we identified a fraction of cells in the low-density fraction (~0.025% compared to total RBCs population) which shows reversal in their densities along with the characteristics of cellular senescence such as loss of membrane Band 3 protein and the phosphatidylserine exposure to the outer membrane leaflet. Our subsequent analysis showed that these cells are overloaded with Ca<sup>2+</sup>. We further measured intracellular [Na<sup>+</sup>] in individual RBCs by flow cytometry utilizing the dye CoroNa Green-AM. Our findings showed that the cells with senescent characteristics lost their transmembrane Na<sup>+</sup> gradient despite maintaining the membrane integrity. Consequently, these findings lead us to designate these cells as “senescent-like” cells. Our data further demonstrated altered activities of nonselective cation channels and pumps in these cells. In addition to a facilitated Na+ extrusion by Na<sup>+</sup>, K+-ATPase, our findings indicated altered ion transport via Piezo1 in these cells. Pharmacological modulation of Piezo1 with Yoda1/GsMTx4 showed that Piezo1 and, possibly, other nonselective cation channels by promiscuously transporting Na<sup>+</sup> and Ca<sup>2+</sup> play an important role in producing these low density “senescent like” cells.
DOI: 10.5281/zenodo.5839742
title: Terminal density reversal and the role of Ca2+ in red blood cells clearance of healthy individuals

description: Density reversal of senescent red blood cells (RBCs) has been known for more than ten years, yet the identity of the candidate protein(s) is still elusive. While performing Percoll density gradient separation of RBCs from healthy individuals and their subsequent characterization, we identified a fraction of cells in the low-density fraction (~0.025% compared to total RBCs population) which shows reversal in their densities along with the characteristics of cellular senescence such as loss of membrane Band 3 protein and the phosphatidylserine exposure to the outer membrane leaflet. Our subsequent analysis showed that these cells are overloaded with Ca<sup>2+</sup>. We further measured intracellular [Na<sup>+</sup>] in individual RBCs by flow cytometry utilizing the dye CoroNa Green-AM. Our findings showed that the cells with senescent characteristics lost their transmembrane Na<sup>+</sup> gradient despite maintaining the membrane integrity. Consequently, these findings lead us to designate these cells as “senescent-like” cells. Our data further demonstrated altered activities of nonselective cation channels and pumps in these cells. In addition to a facilitated Na+ extrusion by Na<sup>+</sup>, K+-ATPase, our findings indicated altered ion transport via Piezo1 in these cells. Pharmacological modulation of Piezo1 with Yoda1/GsMTx4 showed that Piezo1 and, possibly, other nonselective cation channels by promiscuously transporting Na<sup>+</sup> and Ca<sup>2+</sup> play an important role in producing these low density “senescent like” cells.
DOI: 10.25934/pr00005684.0
title: Available IPD datapackage for study 'A Randomized, Double-Blind, Placebo-Controlled, Phase IIIb Trial Comparing Bevacizumab Therapy With or Without Erlotinib After Completion of Chemotherapy With Bevacizumab for the First-Line Treatment of Locally Advanced, Recurrent, or Metastatic Non-Small Cell Lung Cancer'

description: This is a Phase IIIb, multicenter, randomized, placebo-controlled trial to evaluate the safety and efficacy of chemotherapy+bevacizumab followed by bevacizumab+erlotinib versus bevacizumab+erlotinib placebo in subjects with locally advanced or metastatic NSCLC.
DOI: 10.6084/m9.figshare.17128685
title: Supplementary Material for: Antithrombotic Management in Adult Kidney Transplantation – A European survey study

description: In kidney transplantation (KTx), renal graft thrombosis (RGT) is one of the main reasons for early graft loss. Although evidence-based guidance on prevention of RGT is lacking, thromboprophylaxis is widely used. The aim of this survey was to obtain a European view of the different thromboprophylactic strategies applied in KTx. An online 22-question survey, addressed to KTx professionals, was distributed by e-mail and via platforms of the European Society for Organ Transplantation. Seventy-five responses (21 countries, 51 centers) were received: 75% had over 10 years’ clinical experience, 64% were surgeons, 29% nephrologists and 4% urologists. A written antithrombotic management protocol was available in 75% of centers. In 8 (16%) of centers respondents contradicted each other regarding the availability of a written protocol. Thromboprophylaxis is preferred by 78% of respondents, independent of existing antithrombotic management protocols. Ninety-two percent of respondents indicated that an anticipated bleeding risk is the main reason to discontinue chronic antithrombotic therapy preoperatively. Intraoperatively, 32% of respondents administer unfractionated heparin (400 – 10.000 international units with a median of 5000) in selected cases. Despite an overall preference for perioperative thromboprophylaxis in KTx, there is a high variation within Europe regarding type, timing and dosage, most likely due to the paucity of high-quality studies. Further research is warranted in order to develop better guidelines.